Neurophage Pharmaceuticals
HomeAbout UsOur ScienceNewsCareersContact Us

Our Science

. . . . . . . . . . . . . . . . . . . . . .

GAIM Technology

. . . . . . . . . . . . . . . . . . . . . .

Protein Misfolding Diseases

Alzheimer's Disease

Parkinson's Disease

. . . . . . . . . . . . . . . . . . . . . .

Lead Candidate

. . . . . . . . . . . . . . . . . . . . . .

Resource Links

. . . . . . . . . . . . . . . . . . . . . .

Papers and Posters

. . . . . . . . . . . . . . . . . . . . . .

GAIM Technology

NeuroPhage Pharmaceuticals is developing drugs based on the breakthrough GAIM (general amyloid interaction motif) platform that can target multiple misfolded proteins for the treatment of a broad range of neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple orphan indications (HD, ALS, CJD, PSP, MSA).

GAIM-based therapies use a novel mechanism to:

  • Target a broad spectrum of misfolded proteins (Ab, tau, a-synuclein, prion) by recognizing a common amyloid protein conformation
  • Bind, dissociate and prevent formation of misfolded protein assembliesĀ involved in pathology of neurodegenerative diseases
  • Target key stages of amyloid assembly (oligomers to fibrils to plaques)
  • Block cell-to-cell spread of misfolded proteins

 

GAIM Solution: Novel Structure to Target Misfolded Proteins at Several Stages of Assembly

GAIM Solutions